AIPaSiM
Associazione Italiana
Pazienti Sindrome Mielodisplastica

VIII FORUM NAZIONALE AIPaSiM

ESISTONO NUOVE PROSPETTIVE NELLA CURA DELLE SINDROMI MIELODISPLASTICHE? I MEDICI RISPONDONO

ORBASSANO, 17 giugno 2023 • 10.0 -12.30 SALA ROSSA - DIP. SCIENZE CLINICHE E BIOLOGICHE

Il ruolo del trapianto nelle MDS

Alessandro Busca, AOU Città della Salute, Torino,

Marco De Gobbi, Ospedale S Luigi Gonzaga, Orbassano

Blood Stem Cells



Stem Cells from Self to the Rescue



Stem cells are collected from patient

Patient receives chemotherapy or radiation

Self-donated stem cells are re-infused into patient

Stem Cells from Donor to the Rescue



Dove sono presenti le CSE e come possiamo raccogliere le CSE?

SOURCES OF HEMATOPOIETIC STEM CELLS

BONE MARROW





SOURCES OF HEMATOPOIETIC STEM CELLS

BONE MARROW





PERIPHERAL BLOOD



SOURCES OF HEMATOPOIETIC STEM CELLS

BONE MARROW

PERIPHERAL BLOOD

CORD BLOOD









Quale puo’ essere il donatore di CSE?

Fratello HLA-identico

Familiare parzialmente compatibile

Donatore volontario compatibile

INDICAZIONI AL TRAPIANTO ALLOGENICO

Alterazione severa del compartimento staminale

- **Riduzione quantitativa: anemia aplastica severa (SAA)**
- **Alterazione qualitativa: leucemie, linfomi, MDS**
- **Difetto congenito:**
  - **linea eritropoietica: talassemia**
  - **linea granulocito-monocito-macrofagica: Kostman, osteopetrosi, Chediak-Higashi**
  - **linfopoietica: SCID**
  - **deficit enzimatici: mucopolisaccaridosi**

2021 – 694 Centri europei

47.412 HSCT

19.806 allogenico (42%)

27.606 autologo (58%)

2524 CAR-T







Fig. 4 Change in choice of donor type in Europe from 1990 to 2021.


Allogeneic Transplants
(n = 44.160)
N. of Transplants
Years
3000
2500
2000
1500
1000
500
0
2452
445
472
531
558
669
743
784
886
1054
1065
1157
1215
1313
1299
1419
1450
1490
1496
1603
1687
1762
1717
1766
1737
1807
1960
1909
1945
1928
1910
1931
<1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Export date 09/03/2023


Allogeneic Transplants - Indications 2023
Hem; 26
HistDis; 9
Other; 82
ID; 33
InhDisM; 9
ST; 5
AA; 62
MM/PCD; 21
NHL; 115
HD; 54
CLL; 21
AML; 855
MDS; 178
MPN; 90
CML; 32
ALL; 339


Allogeneic Transplants – Donor type
Ident.Sib
Unrelated
Fam.Mismatch/Aplo
Fam.Match
N. of Transplants
1200
1000
800
600
400
200
0
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Years
380
883
655
359
939
603
378
970
577
50,2%
29,9%
19,6%
Export date 09/03/2023

Allogeneic Transplants – Patient age at transplantation



Export date 09/03/2023

Complicanze post-trapianto

GRADING GVHD

ORGANO	ESTENSIONE		STADIO
CUTE	RASH < 25%		+
	25-50%		++
	> 50%		+++
	BOLLE		++++
FEGATO		2-3	+
	BILIR.	3.1-6	++
	mg%	6.1-15	+++
		>15	++++
INTESTINO	DIARREA ml/die	>500	+
		>1.000	++
		>1.500	+++
	DOLORE ILEO		++++
PERF.ST.	COMPROMISS.		+
			++
			+++

GRADO



SIGNS & SYMPTOMS of Chronic GVHD

ORGAN/SITE	
SKIN	Erythema, maculopapular rash, pruritus, poikiloderma, lichen-like features
NAILS	dystrophy
SCALP	alopecia
MOUTH	Lichen, xerostomia, mucositis
EYES	Keratoconjunctivitis sicca, photophobia, blepharitis
GI tract	Strictures of oesophagus, anorexia, weight loss
LIVER	Bilirubin or ALP > 2 x ULN
LUNG	BOS
MUSCLES, JOINTS	Fascitis, joint contractures, myositis, cramps, arthralgias
HEMATOPOIETIC & IMMUNE	Thrombocytopenia, eosinophilia, lymphopenia
OTHER	Ascites, pericardial or pleural effusion

MDS: Indicazioni al trapianto di midollo osseo

RISCHIO BASSO
(IPPS-R basso e molto basso)

RISCHIO INTERMEDIO

RISCHIO ALTO
(IPPS-R alto e molto alto)

- refrattarietà/recidiva alle terapie
- citopenia severa e sintomatica
- elevata trasfusione-dipendenza
- **alterazioni citogenetiche e molecolari sfavorevoli**